Rocket Pharmaceuticals reported second quarter 2026 financial results and operational updates. The company generated $123.2 million in net income, driven by a $178.2 million gain from the sale of its Priority Review Voucher for KRESLADI. Cash, cash equivalents, and investments totaled $283.7 million as of June 30, 2026, providing an expected runway into the second quarter of 2028. Research and development expenses decreased to $29.5 million from $42.7 million in the prior year period. Clinically, all three initial patients treated with RP-A501 for Danon disease completed the safety observation period without significant concerns, and Rocket is engaging with the FDA on completing the pivotal Phase 2 trial. Commercialization preparations for KRESLADI are underway for patient onboarding in the fourth quarter of 2026. The company operates as a commercial-stage biotechnology firm developing genetic medicines for rare disorders.
